SS
RYTM icon

Steve Schonfeld’s Rhythm Pharmaceuticals RYTM Stock Holding History

Steve Schonfeld’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Buy
+28,607
New +$2.59M 0.01% 835
2025
Q3 		– Sell
-77,983
Closed -$4.93M – 2526
2025
Q2 		$4.93M Buy
77,983
+20,833
+36% +$1.28M 0.03% 568
2025
Q1 		$3.03M Sell
57,150
-2,550
-4% -$141K 0.02% 749
2024
Q4 		$3.34M Buy
59,700
+29,165
+96% +$1.61M 0.02% 628
2024
Q3 		$1.6M Buy
30,535
+19,614
+180% +$940K 0.01% 985
2024
Q2 		$448K Buy
+10,921
New +$436K ﹤0.01% 1532
2023
Q2 		– Sell
-13,311
Closed -$237K – 2447
2023
Q1 		$237K Sell
13,311
-107,378
-89% -$2.7M ﹤0.01% 1468
2022
Q4 		$3.51M Buy
120,689
+71,786
+147% +$1.84M 0.03% 596
2022
Q3 		$1.2M Buy
+48,903
New +$909K 0.01% 1157
2018
Q4 		– Sell
-47,100
Closed -$1.37M – 1216
2018
Q3 		$1.37M Sell
47,100
-48,900
-51% -$1.55M 0.06% 368
2018
Q2 		$3M Buy
+96,000
New +$2.62M 0.16% 207

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steve Schonfeld's RYTM Position: Q2 2026 in Review

Steve Schonfeld opened a new position in Rhythm Pharmaceuticals (RYTM) in Q2 2026: 28,607 shares worth $3.18M. The stake represents 0.01% of the portfolio and ranks #835 among its holdings. This is a return to the name: Steve Schonfeld previously reported a position in RYTM as recently as Q2 2025.

Steve Schonfeld first reported a position in RYTM in Q2 2018 and has held it in 11 quarters since. The position peaked at $4.93M in Q2 2025. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Steve Schonfeld held 28,607 shares of Rhythm Pharmaceuticals worth $3.18M as of Q2 2026.
  • Rhythm Pharmaceuticals was a new Steve Schonfeld position in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.01% of Steve Schonfeld's portfolio in Q2 2026, its #835 holding.
  • Steve Schonfeld first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 11 quarters since.
  • Steve Schonfeld's Rhythm Pharmaceuticals position peaked at $4.93M in Q2 2025.
  • 300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.